<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T02:01:39Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/110768" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/110768</identifier><datestamp>2025-12-05T00:49:11Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478917</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Ivermectin to reduce malaria transmission I. Pharmacokinetic and&#xd;
                pharmacodynamic considerations regarding efficacy and safety</dc:title>
   <dc:creator>Chaccour, Carlos</dc:creator>
   <dc:creator>Hammann, Felix</dc:creator>
   <dc:creator>Rabinovich, Regina</dc:creator>
   <dc:subject>Malària</dc:subject>
   <dc:subject>Medicina tropical</dc:subject>
   <dc:subject>Farmacocinètica</dc:subject>
   <dc:subject>Malaria</dc:subject>
   <dc:subject>Tropical medicine</dc:subject>
   <dc:subject>Pharmacokinetics</dc:subject>
   <dcterms:abstract>Ivermectin is an endectocide that has been used broadly in&#xd;
                single dose community campaigns for the control of&#xd;
                onchocerciasis and lymphatic filariasis for more than 30 years.&#xd;
                There is now interest in the potential use of ivermectin&#xd;
                regimens to reduce malaria transmission, envisaged as&#xd;
                community-wide campaigns tailored to transmission patterns and&#xd;
                as complement of the local vector control programme. The&#xd;
                development of new ivermectin regimens or other novel&#xd;
                endectocides will require integrated development of the drug in&#xd;
                the context of traditional entomological tools and endpoints.&#xd;
                This document examines the main pharmacokinetic and&#xd;
                pharmacodynamic parameters of the medicine and their potential&#xd;
                influence on its vector control efficacy and safety at&#xd;
                population level. This information could be valuable for trial&#xd;
                design and clinical development into regulatory and policy&#xd;
                pathways.</dcterms:abstract>
   <dcterms:issued>2017-05-10T13:25:54Z</dcterms:issued>
   <dcterms:issued>2017-05-10T13:25:54Z</dcterms:issued>
   <dcterms:issued>2017-04-24</dcterms:issued>
   <dcterms:issued>2017-05-03T18:01:29Z</dcterms:issued>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:relation>Reproducció del document publicat a:&#xd;
                http://dx.doi.org/10.1186/s12936-017-1801-4</dc:relation>
   <dc:relation>Malaria Journal, 2017, vol. 16, num. 1, p. 161</dc:relation>
   <dc:relation>http://dx.doi.org/10.1186/s12936-017-1801-4</dc:relation>
   <dc:rights>cc by (c) Chaccour et al., 2017</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:publisher>Biomed Central</dc:publisher>
   <dc:source>Articles publicats en revistes (ISGlobal)</dc:source>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>